Last updated: August 4, 2026
Lenvatinib mesylate, marketed primarily as LENVIMA by Eisai, is a differentiated oral tyrosine kinase inhibitor with approved uses in thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and endometrial cancer. Its commercial value is driven by combination therapy with pembrolizumab and everolimus rather than by monotherapy alone. Global sales have reached the billion-dollar range annually, with further growth dependent on oncology-line expansion, international uptake, and protection from generic competition.
What is lenvatinib mesylate and how is it marketed?
Lenvatinib mesylate is the mesylate salt of lenvatinib, a multi-kinase inhibitor targeting VEGFR1-3, FGFR1-4, PDGFR-alpha, RET, and KIT. Eisai developed and commercializes LENVIMA. Merck & Co. is Eisai’s strategic partner for the pembrolizumab combination under the KEYTRUDA and LENVIMA collaboration.
| Product |
Active ingredient |
Primary companies |
Dosage form |
Main commercial role |
| LENVIMA |
Lenvatinib mesylate |
Eisai; Merck collaboration for selected combinations |
Oral capsules |
Multi-indication oncology product |
| KEYTRUDA plus LENVIMA |
Pembrolizumab plus lenvatinib |
Merck and Eisai |
IV plus oral therapy |
Endometrial carcinoma and renal cell carcinoma |
| LENVIMA plus everolimus |
Lenvatinib plus everolimus |
Eisai |
Oral combination |
Advanced renal cell carcinoma |
LENVIMA does not have biosimilar exposure because lenvatinib is a chemically synthesized small molecule. Its principal future threat is generic substitution after relevant small-molecule patents and regulatory exclusivity expire.
What FDA-approved indications drive lenvatinib demand?
The FDA-approved indications are broad, but revenue concentration is highest in thyroid cancer and combination oncology.
| Indication |
FDA milestone |
Treatment setting |
| Differentiated thyroid cancer |
2015 |
Progressive, radioactive iodine-refractory disease |
| Renal cell carcinoma |
2016 |
Advanced disease with everolimus |
| Hepatocellular carcinoma |
2018 |
Unresectable disease, first-line treatment |
| Endometrial carcinoma |
2021 |
Advanced or recurrent disease with pembrolizumab after prior systemic therapy |
| Advanced renal cell carcinoma |
2021 |
First-line pembrolizumab plus lenvatinib |
The endometrial-cancer approval expanded LENVIMA into a larger immuno-oncology market, but uptake depends on treatment sequencing, reimbursement, toxicity management, and competition from chemotherapy-immunotherapy combinations.
The renal-cell-carcinoma combination with pembrolizumab competes directly with established regimens including pembrolizumab plus axitinib, nivolumab plus cabozantinib, and ipilimumab plus nivolumab. In hepatocellular carcinoma, lenvatinib competes with atezolizumab plus bevacizumab and durvalumab plus tremelimumab. In thyroid cancer, it competes with sorafenib and other targeted options.
How large is the lenvatinib market?
LENVIMA has developed into one of Eisai’s most important products. Public company reporting places annual global LENVIMA sales in the approximately $1.5 billion to $2 billion range in the most recent reporting period, depending on currency conversion and whether reported product sales or collaboration economics are used.
| Metric |
Commercial interpretation |
| Global annual sales |
Billion-dollar oncology franchise |
| Lead company |
Eisai |
| Key growth partner |
Merck through pembrolizumab combinations |
| Largest value driver |
Combination therapy, particularly pembrolizumab plus lenvatinib |
| Principal markets |
United States, Japan, China, and Europe |
| Revenue risk |
Generic entry, pricing pressure, competing checkpoint-inhibitor regimens |
Eisai’s reported LENVIMA growth has been supported by the expansion of combination indications and by increased use in the United States and China. The product has a larger addressable market than its original differentiated-thyroid-cancer indication because renal cell carcinoma and endometrial cancer provide access to higher-volume immuno-oncology segments.
What is the financial trajectory for LENVIMA?
The financial trajectory has three phases:
- Initial growth from differentiated thyroid cancer.
- Expansion through hepatocellular carcinoma and renal cell carcinoma.
- Acceleration through pembrolizumab combination therapy.
Eisai has described LENVIMA as a core growth product in its medium-term strategy. The company’s commercial model benefits from the product’s use across multiple tumor types, although sales are exposed to concentration in oncology prescribing and to the economic terms of the Merck collaboration.
Revenue growth factors
The main positive revenue factors are:
- Increased use of pembrolizumab plus lenvatinib in advanced endometrial cancer.
- First-line renal cell carcinoma adoption.
- Expansion in China and other international markets.
- Continued use in radioactive iodine-refractory thyroid cancer.
- New clinical data supporting earlier-line or additional combination use.
- Higher treatment duration in patients who remain on therapy despite dose reductions.
Revenue constraints
The principal constraints are:
- Hypertension, proteinuria, fatigue, diarrhea, and other adverse events that can require dose interruption.
- Competition from other VEGFR and immune-checkpoint combinations.
- Reimbursement restrictions for combination regimens.
- The availability of lower-cost generic lenvatinib after patent expiry.
- Potential erosion in mature thyroid-cancer markets.
- Reduced duration of therapy in patients unable to tolerate the recommended dose.
Lenvatinib’s sales profile is therefore more durable than that of a single-indication kinase inhibitor, but its growth rate should moderate as the combination franchise matures.
How does lenvatinib compare with competing oncology drugs?
Lenvatinib versus axitinib
Lenvatinib has broader kinase activity and is used with pembrolizumab in renal cell carcinoma. Axitinib is a more selective VEGFR inhibitor and is also paired with pembrolizumab. Competition is based on overall survival, response rate, toxicity, physician familiarity, dosing, and payer policy.
Lenvatinib’s potential advantages include strong response activity and a broader clinical development platform. Axitinib benefits from established first-line use and a long commercial history.
Lenvatinib versus cabozantinib
Cabozantinib has activity against MET, AXL, and VEGFR pathways and is used in renal cell carcinoma and hepatocellular carcinoma. Its positioning is strong in later-line renal cell carcinoma. Lenvatinib has a stronger commercial association with pembrolizumab and a broader thyroid-cancer franchise.
Lenvatinib versus sorafenib
Sorafenib was an earlier standard in thyroid cancer and hepatocellular carcinoma. Lenvatinib generally gained share through higher response rates in radioactive iodine-refractory thyroid cancer and strong activity in hepatocellular carcinoma. Sorafenib’s lower-cost generic availability creates pricing pressure.
Lenvatinib versus checkpoint-inhibitor combinations
In endometrial cancer, pembrolizumab plus lenvatinib competes with dostarlimab-based and chemotherapy-immunotherapy approaches. The choice depends on mismatch-repair status, prior treatment, toxicity, treatment guidelines, and payer restrictions.
What patents protect LENVIMA and when does lenvatinib lose exclusivity?
Lenvatinib’s United States patent estate includes composition-of-matter, formulation, method-of-use, and combination-treatment claims. The earliest core U.S. composition patent has been publicly associated with U.S. Patent No. 7,612,224, which has a listed expiration in the mid-2020s before any applicable patent-term adjustment or pediatric extension.
The commercial exclusivity picture is more complex than the earliest compound patent because later patents can cover:
- Lenvatinib formulations and dosage forms.
- Treatment of radioactive iodine-refractory thyroid cancer.
- Combination use with everolimus.
- Combination use with pembrolizumab.
- Specific dosing or patient-selection methods.
- Solid formulations and manufacturing processes.
| Protection category |
Commercial purpose |
Likely erosion timing |
| Core compound patent |
Protects lenvatinib chemical entity |
Mid-2020s |
| Formulation patents |
Protect capsules, compositions, or release characteristics |
Mid- to late-2020s |
| Thyroid-cancer method patents |
Protect treatment of selected patients |
Potentially late 2020s |
| Everolimus combination patents |
Protect renal cell carcinoma combination |
Potentially late 2020s or early 2030s |
| Pembrolizumab combination patents |
Protect immuno-oncology regimen |
Potentially into the early 2030s |
| Regulatory exclusivity |
FDA NCE, orphan, or pediatric protections where applicable |
Indication-specific |
The practical generic-entry date depends on which patents are listed in the Orange Book, whether generic applicants file Paragraph IV certifications, litigation outcomes, settlements, and whether a court grants an injunction. A compound patent expiration does not automatically permit unrestricted substitution if method-of-use or formulation patents remain enforceable.
What is the Orange Book status of LENVIMA?
LENVIMA is an FDA-approved small-molecule product subject to Orange Book patent listing. Orange Book-listed patents can create a 30-month stay if the innovator files a timely infringement action after receiving a Paragraph IV notice.
The relevant commercial questions are:
- Which patents remain listed for each approved strength and dosage form?
- Which listed patents have expired?
- Whether generic applicants use Paragraph III certifications or Paragraph IV challenges.
- Whether claims cover the proposed generic label or only patented uses.
- Whether the FDA applies a skinny-label pathway for unpatented indications.
Because LENVIMA has multiple oncology indications, a generic applicant may attempt to remove patented uses from its label while retaining nonpatented indications. That strategy can reduce litigation exposure but does not eliminate the risk of induced-infringement allegations if the marketing conduct encourages use of the patented regimen.
Which companies are likely to challenge LENVIMA patents?
The most likely challengers are large generic manufacturers with oncology distribution and regulatory infrastructure. Potential participants in the competitive field include Teva, Sandoz, Dr. Reddy’s Laboratories, Sun Pharma, Cipla, Viatris, Zydus, and Hikma, although a company’s presence in the broader oncology-generic market does not establish a specific LENVIMA filing.
A Paragraph IV challenge would likely focus on one or more of the following:
- Invalidity of the core compound or formulation claims.
- Noninfringement based on a proposed product design.
- Lack of enforceability.
- Expiration of the relevant patent before commercial launch.
- Carve-out of protected methods from the generic label.
The highest-value target is the United States market because it combines high oncology pricing with substantial utilization. Europe, Japan, China, India, and other jurisdictions will follow separate patent and regulatory pathways.
What patent litigation and settlement risks affect generic launch?
A generic applicant that files a Paragraph IV certification can trigger litigation under the Hatch-Waxman Act. The resulting case can delay approval through the statutory 30-month stay, subject to court decisions and patent-listing issues.
A settlement may include:
- A licensed entry date before the latest patent expiry.
- Royalty payments to Eisai.
- Restrictions on the generic’s launch timing.
- A non-cash commercial arrangement.
- No admission of validity or infringement.
- Separate treatment for different indications.
The economic effect of a settlement depends on whether entry is authorized before or after core patent expiry. An early authorized generic or licensed generic could reduce the value of later method-of-use patents even if those patents remain legally valid.
No major publicly established settlement should be treated as the base case without a current review of FDA litigation records, federal court dockets, and company disclosures.
How strong is the lenvatinib patent estate?
The estate is moderately strong commercially because it combines a foundational compound patent with later indication and combination claims. Its legal strength varies by claim type.
Stronger elements
- Core chemical-entity protection has historically provided the primary barrier to generic entry.
- Combination patents may protect high-value pembrolizumab and everolimus regimens.
- Multiple indications create opportunities for label carve-outs and litigation.
- Clinical evidence supports commercially important uses rather than marginal formulations alone.
Weaker elements
- Earlier compound protection is approaching or has reached expiration in key markets.
- Method-of-use claims can be vulnerable to invalidity, written-description, enablement, or obviousness challenges.
- Generic applicants can use skinny-label strategies.
- Patent expiry differs across jurisdictions.
- Combination claims may face obviousness arguments based on known VEGFR inhibitors and checkpoint inhibitors.
LENVIMA’s commercial defense is therefore based on a layered patent estate and brand recognition, not on a single late-expiring patent.
What generic launch scenarios exist for lenvatinib?
Scenario 1: Delayed entry after compound and formulation expiry
This is the most favorable outcome for Eisai. Generic entry occurs only after the principal listed patents expire or are invalidated, preserving branded sales during the remaining patent period.
Scenario 2: At-risk launch
A generic manufacturer launches before final resolution of patent litigation. This can create rapid price erosion, damages exposure, and potential market withdrawal if Eisai prevails.
Scenario 3: Licensed early entry
Eisai settles with one or more applicants and permits launch before the latest listed patent expiry. Sales decline begins earlier, but litigation uncertainty is reduced.
Scenario 4: Skinny-label competition
Generic manufacturers launch for unprotected indications while excluding patented combination or method-of-use language. The product can still pressure LENVIMA sales because pharmacies and prescribers may substitute across overlapping uses.
Scenario 5: Authorized generic
Eisai or a partner introduces an authorized generic to capture part of the post-expiry market and moderate the price decline. This strategy can reduce third-party generic margins but also accelerates lower-price availability.
What manufacturing and intellectual-property barriers protect lenvatinib?
Manufacturing barriers are less durable than compound patents but can affect early generic competition. Relevant areas include:
- Control of the lenvatinib active pharmaceutical ingredient.
- Salt formation and crystallization.
- Impurity specifications.
- Capsule composition.
- Bioequivalence across strengths.
- Stability and dissolution performance.
- Supply qualification for oncology distribution.
- Manufacturing know-how for consistent commercial-scale production.
Because LENVIMA is an oral small molecule, manufacturing complexity is lower than for biologics. Generic entrants do not face cell-line, biosimilar comparability, or clinical immunogenicity barriers. The most important barriers are patent timing, regulatory approval, API sourcing, and payer access.
What is the geographic market outlook for lenvatinib?
The United States remains the highest-value market. Japan is strategically important to Eisai because of its domestic commercial base and regulatory position. China offers substantial volume potential but carries price and procurement risk. Europe has broad clinical access but greater pricing controls and country-level reimbursement variation.
| Region |
Growth opportunity |
Main risk |
| United States |
Combination oncology and high treatment value |
Paragraph IV litigation and generic erosion |
| Japan |
Eisai infrastructure and established oncology use |
Mature market and reimbursement controls |
| China |
Large patient population and broader diagnosis |
National procurement and price reductions |
| Europe |
Multiple approved indications |
Reference pricing and fragmented reimbursement |
| Emerging markets |
Volume growth |
Lower prices, local competitors, regulatory variation |
Patent expiry may occur at different times across these regions. A company cannot use United States patent timing as a proxy for worldwide exclusivity.
How much revenue is exposed to generic entry?
LENVIMA represents a material share of Eisai’s growth profile. A broad generic launch could affect:
- Product sales directly.
- Eisai’s collaboration economics with Merck.
- Forecasted oncology growth.
- Cash flow available for research and business development.
- Valuation assumptions tied to the duration of the LENVIMA franchise.
The decline pattern will depend on the number of entrants. One or two controlled entrants may produce moderate erosion. Five or more approved generics can create rapid price compression, particularly in the pharmacy channel. Combination therapy may delay some erosion because oncologists and payers may distinguish branded combination evidence from generic monotherapy, but the active ingredient remains substitutable where the generic label covers the same use.
What licensing deals affect lenvatinib?
Eisai and Merck entered a global strategic collaboration covering the development and commercialization of LENVIMA with KEYTRUDA. The collaboration includes combination development in solid tumors and shared commercial interests in approved or subsequently developed indications.
The agreement has two important market effects:
- It increased clinical-development resources and expanded LENVIMA into immuno-oncology.
- It complicates revenue attribution because Eisai product sales and Merck collaboration economics are not equivalent to standalone LENVIMA revenue.
The collaboration is a commercial asset while the combination indications remain differentiated. It also creates dependence on Merck’s KEYTRUDA franchise, clinical priorities, and contracting strategy.
Key Takeaways
- Lenvatinib mesylate is a large, multi-indication oncology franchise marketed as LENVIMA.
- Its highest commercial value comes from pembrolizumab and everolimus combinations.
- Global annual sales are in the approximately $1.5 billion to $2 billion range based on recent public-company reporting and currency conversion.
- The United States is the most important market for revenue and generic-entry risk.
- The core composition patent is approaching or has reached expiry in key markets, while later formulation, method-of-use, and combination patents may extend protection.
- Lenvatinib has no biosimilar risk because it is a small molecule.
- Generic-entry timing will depend on Orange Book listings, Paragraph IV filings, litigation, settlements, and possible skinny-label launches.
- The commercial outlook remains positive before broad generic entry but should moderate as renal cell carcinoma and endometrial cancer competition increases.
FAQs
Does lenvatinib have biosimilar competition?
No. Lenvatinib is a synthetic small molecule, so competitive products are regulated as generics rather than biosimilars.
Is LENVIMA stronger commercially as monotherapy or combination therapy?
Combination therapy is the stronger growth driver. Pembrolizumab and everolimus combinations expanded LENVIMA into larger renal cell carcinoma and endometrial cancer markets.
Will generic lenvatinib automatically replace LENVIMA?
Not in every use. Substitution depends on the generic label, pharmacy rules, payer policy, dosage strength, indication, and remaining method-of-use patents.
What is the main financial risk to Eisai from lenvatinib?
The main risk is accelerated generic erosion after relevant U.S. and international patents expire or are bypassed through litigation, settlement, or skinny-label strategies.
Does the Merck collaboration reduce Eisai’s LENVIMA revenue?
The collaboration changes how economics are shared and reported, but it also expands the product’s clinical use and commercial reach. The effect on reported revenue depends on the accounting treatment and terms applicable to each indication.
References
-
Eisai Co., Ltd. (2024). Annual report 2024. Eisai Co., Ltd.
-
Merck & Co., Inc. (2024). Annual report 2023. Merck & Co., Inc.
-
U.S. Food and Drug Administration. (2024). LENVIMA (lenvatinib mesylate) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2015). FDA approves lenvatinib for radioactive iodine-refractory differentiated thyroid cancer. FDA.
-
U.S. Food and Drug Administration. (2018). FDA approves lenvatinib for unresectable hepatocellular carcinoma. FDA.
-
U.S. Food and Drug Administration. (2021). FDA approves pembrolizumab plus lenvatinib for advanced endometrial carcinoma. FDA.
-
Eisai Co., Ltd., & Merck & Co., Inc. (2018). Strategic collaboration agreement for the development and commercialization of LENVIMA and KEYTRUDA combinations. Company disclosure.
